BioSpace News Archive

Fulgent Genetics, Inc. announced the addition of Reggie Groves to its board of directors, effective January 3, 2023.

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, highlighted its strategic outlook for 2023 and planned 2023 corporate milestones, and announced preliminary unaudited fourth quarter and full year 2022 revenue.

SI-BONE, Inc., a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announced that the company will be participating in the upcoming 25th Annual Needham Growth Conference.

Aurinia Pharmaceuticals Inc. announced that the Company’s Compensation Committee granted 2 new employees inducement stock options to purchase an aggregate of 12,650 common shares, at a per share exercise price of $5.94, the closing price of Aurinia’s common stock on January 3, 2023, and an aggregate of 7,730 inducement restricted stock units.

Transcenta Holding Limited (“Transcenta”) (HKEX: 06628) announces that TST003, its first-in-class, high affinity humanized monoclonal antibody targeting Gremlin1, has received IND clearance from the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA).

MedMira Inc. announces the publication of Point-of-Care Diagnostic for Trichomonas vaginalis, the Most Prevalent, Non-Viral Sexually Transmitted Infection -, in the special edition of Pathogens by MDPI, a Swiss based medical journal.

Navidea Biopharmaceuticals, Inc. today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent application titled, “Compositions And Methods For Altering Macrophage Phenotype (US Application #16/832,620).”

CardieX Limited today announced a partnership between its ATCOR subsidiary and Invaryant, a data-driven health technology company that empowers individuals with precision AI to improve quality, equity and safety, and provides comprehensive, integrated, high quality data to accelerate research and innovation.

Multi Radiance Veterinary, leading developer of therapeutic laser technology, and Digatherm Thermal Imaging, a division of Infrared Cameras, Inc., are pleased to announce a commercial partnership.

Burning Rock (NASDAQ/LSE: BNR), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that its OverC™ Multi-Cancer Detection Blood Test (MCDBT) has been granted Breakthrough Device Designation by the US Food and Drug Administration (FDA), which is the third of its kind globally.